SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : CLTX: Celsus Therapeutics
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: keokalani'nui who wrote (32)3/8/2002 1:33:41 AM
From: Miljenko Zuanic  Read Replies (1) of 40
 
Article (tanks Lora Pike) is very professional and well balanced. As layman I can understand what were their objective and concern in PI/II trial, and what collected data represent.

Certainly there is optimism that Ad5-FGF4 can delivery manful medical benefit and with low risk for serious ASE. Hapatotoxicity will be closely monitored. Again, I do not think (or believe) that malignancy should be concern. Unless pts has precancerous condition or existing cancer (in case that vector accumulate at cancer site, no detectable FGF-4 in plasma).

Anyway, 20-30% ETT improvement at statistical significance (for baseline ETT <12 min) should not be difficult to achieve. I do expect (or hope) additional medical benefits as well.

Miljenko
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News